Lung cancer 2017: Giant steps and stumbling blocks
Lung cancer 2017: Giant steps and stumbling blocksLung cancer 2017: Giant steps and stumbling blocks, Published online: 21 November 2017; doi:10.1038/nrclinonc.2017.178In 2017, major advances in the treatment of non-small-cell lung cancer (NSCLC) continued to emanate from the fields of molecularly targeted therapy and immunotherapy. In the former, new drugs with improved efficacy and reduced toxicity entered the clinic; in the latter, immune-checkpoint inhibition proved efficacious after chemoradiotherapy for stage III disease, but had disparate results in the frontline treatment of stage IV disease.
Source: Nature Clinical Practice Oncology - Category: Cancer & Oncology Authors: David F. Heigener Martin Reck Source Type: research
More News: Cancer | Cancer & Oncology | Immunotherapy | Lung Cancer | Non-Small Cell Lung Cancer | Toxicology